| Previous close | 7.1000 |
| Open | 2.5500 |
| Bid | 0.6000 |
| Ask | 2.5000 |
| Strike | 360.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.5500 - 2.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 204 |
GlobeNewswireargenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company
ZacksArgenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Investor's Business DailyArgenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.
